MASLD Patients Have More Comorbidities, Higher Death Risk
A higher burden of multimorbidity was seen in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) than in individuals without MASLD, with a higher risk for all-cause mortality observed in those with MASLD and multimorbidity.
METHODOLOGY:
In this large UK-based study, researchers determined the prevalence of multimorbidity in individuals with MASLD and assessed how MASLD, alongside the extent of multimorbidity, affects all-cause mortality.
The analysis included data of 438,840 participants (mean age, 56.5 years; 42.2% men) from the UK Biobank who were recruited between 2006 and 2010.
The diagnosis of MASLD was confirmed if patients had liver steatosis (fatty liver index ≥ 60%), at least one cardiometabolic risk factor, and low alcohol consumption.
Overall, 47 long-term conditions were considered, including extrahepatic cancers; cardiovascular, metabolic, and endocrine disorders; and respiratory, digestive, renal, mental health, and congenital conditions. Multimorbidity was defined as having more than two of these long-term conditions.
The outcome was all-cause mortality, assessed over a median follow-up duration of 13 years.
TAKEAWAY:
At baseline, 29.9% of participants had MASLD, with a higher prevalence of multimorbidity than that in those without MASLD (21.3% vs 14.4%).
MASLD was associated with an increased risk for all-cause mortality (adjusted hazard ratio [aHR], 1.16; 95% CI, 1.13-1.19), with stronger effects seen in women (aHR, 1.25; 95% CI, 1.20-1.29) than in men (aHR, 1.10; 95% CI, 1.07-1.13).
Patients with MASLD were more likely to have 32 out of the 47 long-term conditions. Each additional long-term condition increased the risk for mortality by 30% in patients with MASLD (aHR, 1.30; 95% CI, 1.29-1.31) and by 38% in individuals without MASLD (aHR, 1.38; 95% CI, 1.37-1.40).
The most prevalent cardiometabolic risk factor in patients with MASLD was obesity (98.9%), and among all long-term conditions, Parkinson's disease showed the highest risk for mortality in those with MASLD (aHR, 6.09; 95% CI, 4.47-8.29).
IN PRACTICE:
"Addressing multimorbidity in MASLD patients through multidisciplinary and proactive management of multimorbidity is crucial to improving patient outcomes and reducing the overall public health impact of MASLD," the authors of the study wrote.
SOURCE:
This study was led by Qi Feng, The George Institute for Global Health (UK), School of Public Health, Faculty of Medicine, Imperial College London, London, England. It was published online on June 10, 2025, in The Journal of Clinical Endocrinology and Metabolism .
LIMITATIONS:
The predominantly White, more affluent UK Biobank cohort may not have reflected the wider UK population, further limiting the generalisability of the findings to other populations. Reliance on self-reported lifestyle data covering physical activity, smoking, and alcohol consumption may have led to information bias, potentially resulting in the misclassification of MASLD vs alcohol-related liver disease.
DISCLOSURES:
This study was supported by the National Institute for Health and Care Research Imperial Biomedical Research Centre. The authors reported having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The European Space Agency and Dassault Aviation paving the way for potential collaborations
PRESS RELEASE June 20, 2025 The European Space Agency and Dassault Aviation paving the way for potential collaborationsThe European Space Agency (ESA) has signed a Letter of Intent (LoI) with Dassault Aviation, a French civilian and military aircraft manufacturer recognized worldwide for its excellence, underlying their common interest to develop a closer relationship. ESA, with its ambitious strategy for space exploration, Explore2040, is seeking innovative solutions for capabilities development to reach and return from Low Earth Orbit (LEO), Moon and Mars, and supports the advancement of selected critical enabling technologies to be used and demonstrated in particular in LEO, such as hypervelocity re-entry. Dassault Aviation, also a leader in aerospace engineering, is developing its space activities with a focus on the design of a reusable spaceplane based on lifting bodies shapes that bridge aeronautical and space technologies. Their interest in automated LEO platforms suitable for commercial and institutional markets, led them to develop a vehicle concept called 'Véhicule Orbital Réutilisable de Transport et d'Exploration (VORTEX)', designed for research in space, transport of cargo to and from space stations, and a range of in-orbit services. This project is based on a considerable expertise in spaceplanes having participated in numerous programmes like Hermes, NASA X-38 Crew Rescue vehicle, ESA Intermediate eXperimental Vehicle (IXV) demonstrator, and Airborne Reusable Hypersonic Experimental Vehicle (VEHRA) concepts. 'Dassault Aviation's decades of expertise in aeronautical and space systems, perfectly position them to pioneer critical space technologies', said Josef Aschbacher, Director General of the European Space Agency. 'With VORTEX, Dassault is contributing to strengthening European capacities and securing sovereign access to space in a strongly growing and competitive space sector. We look forward to combining our expertise and working hand-in-hand for a stronger Europe in space.' 'Our Vortex roadmap aims to strengthen Europe's essential sovereign capabilities and meet the new challenges of the space economy. This letter of intent is a perfect recognition of the complementary expertise of the European Space Agency and Dassault Aviation in the development of critical technologies and innovative space solutions,' declared Eric Trappier, Chaiman and CEO of Dassault Aviation. As such, the signatories of the LoI, have identified a mutual interest in developing a closer relationship with the potential to commonly derisking critical technologies as well as to further explore the potential for collaboration in areas such as LEO destinations and particularly around orbital vehicules. As such, both foresee an interest to cooperate on a scaled down suborbital version of VORTEX, serving as a testbed, with a focus on, but not limited to: Designing, testing and qualifying key technologies and components. New materials and integration processes. Assessing the feasibility to include future payloads in case of the integration of a dedicated bay on the end-product. This joint work will be based on exchanging relevant information and conducting studies or preparatory activities, to help establish respective roles and responsibilities in the realisation of potential joint activities, leveraging on each side's capabilities. 'Europe benefits from a wide range of diverse and complementary skills. Enlarging the European industrial base is key for new opportunities arising in Space Exploration, aiming at more autonomy,' said Daniel Neuenschwander, Director of Human and Robotic Exploration at ESA. About the European Space Agency The European Space Agency (ESA) provides Europe's gateway to is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe's space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. ESA has 23 Member States: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Latvia, Lithuania and Slovakia are Associate Members. ESA has established formal cooperation with other four Member States of the EU. Canada takes part in some ESA programmes under a Cooperation Agreement. By coordinating the financial and intellectual resources of its members, ESA can undertake programmes and activities far beyond the scope of any single European country. It is working in particular with the EU on advancing the Galileo and Copernicus programmes as well as with Eumetsat for the development of meteorological missions. Learn more about ESA at Media contact: media@ About Dassault Aviation With over 10,000 military and civil aircraft delivered in more than 90 countries over the last century, Dassault Aviation has built up expertise recognized worldwide in the design, production, sale and support of all types of aircraft, ranging from the Rafale fighter, to the high-end Falcon family of business jets, military drones and space systems. In 2024, sales amounted to € 6.2 billion. Dassault Aviation has 14,600 employees. Dassault Aviation – PRESS CONTACTS Corporate Communications Stéphane Fort: +33 (0)1 47 11 86 90 - Mathieu Durand: +33 (0)1 47 11 85 88 - Export CommunicationsNathalie Bakhos Tel: +33 (0)1 47 11 84 12 Attachment PR_ESA Dassault VF 1Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Muscles, fats and simple blood test can predict menopausal women's health
SINGAPORE – A simple blood test can predict which woman will have less muscle and will be walking more slowly later in life. It is also practical and cheaper than current methods of measuring muscle, such as the current gold standard magnetic resonance imaging scans or strength tests, which are also more time-consuming. This new insight from a longitudinal cohort study of midlife women in Singapore shone light on how muscle strength, visceral fat and their association with physical decline after menopause can potentially lead to downstream health impacts among women here. Researchers from the National University Hospital (NUH) and National University of Singapore (NUS) found that women with a lower creatinine-to-cystatin C ratio (CCR) – a marker derived from blood tests – had less muscle and walked more slowly as they age. Creatinine is a by-product of normal muscle function and energy use, and a higher level indicates higher skeletal muscle mass or poor kidney function. Cystatin C is a protein produced by the body's cells that is filtered out by the kidneys. A normal cystatin C level rules out poor kidney function. A low CCR of under 8.16 was associated with a lower muscle volume of 0.35 litres in the thigh, and a slower gait of 0.049m a second. This suggested that CCR could be a useful early warning sign for age-related muscle loss, which may lead to falls, frailty and reduced quality of life. The findings were published in Menopause, a monthly peer-reviewed journal, in March. The scientists involved in the study are from the Integrated Women's Health Programme (IWHP) at NUH and the NUS Yong Loo Lin School of Medicine. The IWHP was initiated to identify and address the healthcare needs of midlife Singaporean women. It recruited a cohort of 1,200 Chinese, Malay and Indian women aged 45 to 69 between 2014 and 2016 – about 70 per cent of whom were post-menopausal. Their health metrics were then tracked over time. In the first study based on this cohort, published in international journal Maturitas in October 2023, the researchers shared a ranking of menopausal symptoms – with joint and muscular discomfort found to be the most reported symptom among women in Singapore. Called arthralgia, it had moderate or severe impact on a third of the midlife women of the cohort. A subsequent study, published in the Diabetes, Obesity and Metabolism journal in October 2024, found that women with both weak muscle strength and high levels of visceral fat – the deep belly fat around the internal organs – had the highest risk of developing prediabetes or type 2 diabetes. Their risk was 2.63 times higher than that of women who had normal muscle strength and lower fat levels. Having just one of these conditions also increased their risk, though to a lesser degree. The risk from having high visceral fat alone is 1.78 times higher. Among those with weak muscle strength, women with high visceral fat faced 2.84 times as much risk compared with those with low visceral fat. Explaining the impetus for the study, IWHP lead Yong Eu Leong said: 'Muscle... burns up fat. What about those who have weak muscles? Does it affect the risk for diabetes in the future?' The cohort's initial muscle and visceral fat measurements served as a baseline for researchers to track changes over the years. Researchers then analysed how changes in fat and muscle measurements taken about six years later – by then, about 90 per cent of the women were post-menopausal – related to whether women had developed diabetes. Professor Yong, who also heads the division of benign gynaecology in the Department of Obstetrics and Gynaecology at NUH, noted that a large proportion of women in Singapore are 'skinny fat', where their body mass index is within the normal range, but that they have high levels of visceral fat and low muscle mass. 'One way (to know what your risks are) is to measure your walk and the speed at which you walk. If you cannot walk fast and straight, then your health is not so good. We wanted to see if we can develop a test that can predict gait speed. We wanted to look at molecules that actually measure muscle functions,' he said. 'These findings validated our previous (IWHP) research that showed that women should not just focus on weight loss, but on building muscle strength through exercise for diabetes prevention,' Prof Yong said. One participant of the IWHP, administrative assistant Sabarina Jumarudin, is living proof of the findings. The 59-year-old grandmother used to weigh 93kg and suffered from sleep apnoea. Since undergoing bariatric surgery at NUH in 2018, a procedure that modifies the digestive system to help people with obesity lose weight, she has lost more than 30kg. Mindful of keeping her weight down, Madam Sabarina walks to the MRT station every day instead of taking the shuttle service, and takes the stairs instead of the escalator to catch the train. 'On my way home, I usually take a longer route to ensure I clock at least 10,000 steps a day, and practise stretching and breathing exercises to strengthen my core,' she said. 'I realised that small but consistent changes do make a big impact on my health, so I do what I can on a daily basis, and it gives me confidence to not only stay healthy physically and mentally but also stave off diabetes,' she added. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
Medscape
an hour ago
- Medscape
EMA Recommends Rezdiffra for MASH Liver Fibrosis
The European Medicines Agency (EMA) has recommended conditional marketing authorization for Rezdiffra (resmetirom) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. MASH was formerly known as nonalcoholic fatty liver disease (NASH). There are currently no authorized treatments for MASH in the EU, making Rezdiffra a potential first. MASH is a serious liver disease that occurs when fat accumulates in the liver, causing inflammation. Left untreated, it can lead to cirrhosis and cancer. Symptoms may only present in more advanced stages of the condition, at which point they may include discomfort or pain in the upper right abdomen, muscle weakness or loss, and swelling in the abdomen or legs. Estimates suggest that up to 5% of people in Europe have MASH and that around 25% have metabolic dysfunction‐associated steatotic liver disease (MASLD), the condition that precedes MASH. MASLD was previously known as nonalcoholic fatty liver disease (NAFLD). The active substance of Rezdiffra is resmetirom, which is a partial agonist of the thyroid hormone receptor-beta. It works by promoting lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis. The EMA's decision comes after interim results from a pivotal, ongoing phase 3 trial including 966 adults with biopsy-confirmed MASH with varying stages of fibrosis. Patients were randomly assigned treatment on a 1:1:1 ratio to receive once-daily resmetirom at 80 mg or 100 mg, or a placebo. The primary endpoints were MASH resolution at week 52 with no worsening of fibrosis, and a reduction in fibrosis by at least one stage alongside no worsening of NAFLD activity score. MASH resolution included a reduction in the NAFLD activity score by ≥ 2 points. Scores range from 0 to 8; higher scores indicate more severe disease. After 12 months, 30% of patients in the 100 mg resmetirom group and 26% of those in the 80 mg group achieved MASH resolution with no worsening fibrosis compared with 10% in the placebo group. Meanwhile, 26% of patients in the 100 mg resmetirom group and 24% of patients in the 80 mg group experienced fibrosis improvement by at least one stage with no worsening of NAFLD activity score compared with 14% in the placebo group. The most frequent side effects were diarrhea, nausea, itching, and pruritus. Diarrhea and nausea were more frequent among those taking resmetirom than those taking the placebo. The rate of serious adverse events was similar across all groups and ranged from 10.9% to 12.7%. Rezdiffra will be available as 60 mg, 80 mg, and 100 mg film-coated tablets. It should be taken alongside diet and exercise. The opinion adopted by the EMA will now go to the European Commission to await a decision on EU-wide marketing authorization. In the meantime, the EMA has required Rezdiffra's applicant to complete both the pivotal and another ongoing trial to provide further data regarding the drug's efficacy. This conditional approval comes as the EMA perceives that the benefits to patients from immediate availability outweigh the risk inherent in incomplete data. Detailed recommendations for using Rezdiffra will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages.
